Invion Ltd. · ASX:IVX

Invion — Shareholder Meeting (April 2023)

12 slides from Invion's shareholder meeting presentation, Apr 6, 2023

  1. Slide 1: General Meeting: Expansion of exclusive rights

    For personal use only GENERAL MEETING Expansion of exclusive rights April 2023

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p

  3. Slide 3: New Opportunities: Tapping into US, Canada and HK

    NEW OPPORTUNITIES TAPPING INTO US, CANADA AND HK For personal use only Expanding Invion’s exclusive rights to USA, Canada and Hong Kong for Atherosclerosis and Infections Diseases (AID) Invion to pay $2.5M to RMW for expanded Infectious Diseases rights Invion has option to pay a further $1M (at its

  4. Slide 4: Expanding the Addressable Markets

    EXPANDING THE ADDRESSABLE MARKETS REACHING AN ADDITIONAL 377M PEOPLE For personal use only Current territories New territories for AID AID – Atherosclerosis & Infectious Diseases ID – Infectious Diseases only Indications Existing Territories New Territories Atherosclerosis & ANZ and Asia Pacific exc

  5. Slide 5: Broad-Spectrum Anti-Microbial Potential

    BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL INFECTIOUS DISEASES: EFFECTIVE AGAINST VIRUSES, BACTERIA AND FUNGI IN VITRO For personal use only “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” World Health Organisation1 Leading Institutions: Viroclinics conducted virus “ tests

  6. Slide 6: Effective Against SARS-CoV-2 In Vitro

    EFFECTIVE AGAINST SARS-CoV-2 IN VITRO ANTIVIRAL ACTIVITY AGAINST DELTA AND OMICRON VARIANTS For personal use only SARS-CoV-2: Delta Selected PhotosoftTM Compounds vs. Remdesivir 100 Nine out of ten PhotosoftTM compounds tested displayed antiviral activity against both Delta 80 % Inhibition and Omicr

  7. Slide 7: Effective Against Zika and Dengue In Vitro

    EFFECTIVE AGAINST ZIKA AND DENGUE IN VITRO ANTIVIRAL ACTIVITY AGAINST ZIKA AND DENGUE For personal use only Zika Dengue Inhibition: PhotosoftTM compound vs Monensin1 Inhibition: Selected PhotosoftTM Compounds vs Monensin1 100 100 90 90 Percentage (%) inhibition 80 80 70 70 % Inhibition 60 60 50 50 4

  8. Slide 8: Effective Against Bacteria and Fungi

    EFFECTIVE AGAINST BACTERIA AND FUNGI MRSA SUPERBUG, E.COLI BACTERIA & CANDIDA ALBICANS FUNGUS For personal use only Broad Spectrum Activity: Minimum Inhibition  Several PhotosoftTM compounds showed Concentration (MIC50) of Selected Photosoft Compound following exposure to light for 5 minutes activi

  9. Slide 9: What Is Atherosclerosis

    WHAT IS ATHEROSCLEROSIS KEY CAUSE OF HEART DISEASE DEATHS GLOBALLY For personal use only  Atherosclerosis is a common condition where How Atherosclerosis can cause sticky substances called plaque builds up in disability and death* arteries  Preclinical studies underway to test if Photosoft™ can sa

  10. Slide 10: The Way Forward: Multiple Catalysts and Milestones

    THE WAY FORWARD MULTIPLE CATALYSTS AND MILESTONES For personal use only Australia • Proof of Concept (PoC) Building on in vivo work further demonstrating both safety and efficacy profiles • Pre-clinical Preparations: Building foundations for clinical trials in multiple indications and internationall

  11. Slide 11: Management Team

    MANAGEMENT TEAM THE RIGHT EXPERTISE FOR SUCCESS For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN & CEO CFO • Managing Partner, Polar Ventures • 25+ years in accounting profession • Executive Director, Goldman Sachs • Partner, Vistra • Director, KPMG Consulting, Senior Manager KPMG

  12. Slide 12: Q&A Session

    For personal use only Q&A SESSION ©Copyright Invion Limited| A C N 094 730 417| A S X : I V X 2

Invion — Shareholder Meeting (April 2023) on 6ix